The problem is not just testing. It is access.

Imagine a patient in a village in Rajasthan who visits a nearby Primary Health Center (PHC) but is asked to travel to a larger town for a routine blood test. The test itself may be straightforward, yet the journey adds transportation costs, lost wages, waiting time, and the risk that the patient never completes the test or returns with the result.

This is the last-mile diagnostic gap.

During a recent visit to Mundwa village in Rajasthan, I was reminded that healthcare access depends not only on whether a facility exists, but also on whether the services a patient needs are available when they arrive.

India has built an extensive primary-care network. The opportunity now is to make essential diagnostics more accessible within that network without compromising accuracy, affordability, or quality.

From central laboratories to distributed diagnostics

Central laboratories will remain essential for high-volume testing, specialized investigations, and complex confirmation. The opportunity is not to replace them, but to rethink which tests need to happen where.

A more distributed model could bring community screening closer to people, enable selected point-of-care tests at PHCs, expand diagnostic capabilities at block-level facilities, and connect these facilities to district and reference laboratories for specialized testing and quality oversight.

The right model depends on the clinical use case. Some tests can be performed at the point of care; others still require centralized infrastructure.

The investment opportunity lies in decentralizing selectively, where faster access can improve clinical decisions, reduce patient burden, or make healthcare delivery more efficient.

The technology is evolving, but the real innovation is in the workflow

Several technology pathways could make distributed blood diagnostics more practical:

• Microfluidics and lab-on-chip: Processing small blood volumes through compact cartridges.

• Imaging and AI: Analyzing blood cells and supporting automated cell counting and morphology.

• Portable hematology: Bringing selected complete blood count (CBC) capabilities closer to primary-care settings.

• Non-invasive optical sensing: Estimating parameters such as hemoglobin without conventional blood collection, subject to demonstrated clinical performance.

• Portable hemoglobin-variant testing: Supporting screening and diagnostic pathways for sickle-cell disease and thalassemia.

These technologies are at different stages of technical and clinical maturity. They are not interchangeable: a screening tool, a full blood-count analyzer, and a confirmatory hemoglobinopathy test solve different problems.

But a common opportunity runs across them: making clinically useful testing possible in settings where conventional laboratory infrastructure is difficult to sustain.

The real innovation is not simply making a laboratory instrument smaller. It is simplifying the entire testing process so that reliable results can be generated closer to the patient.

A snapshot of the emerging technology landscape

India's blood-diagnostics ecosystem is exploring several approaches to bringing testing closer to patients. The following companies illustrate different technology pathways rather than a single, directly comparable set of competitors.

Source: Tracxn

These examples represent different types and stages of technology development. They should not be interpreted as a ranking, and inclusion does not imply endorsement or confirmation of current regulatory or commercial status.

The broader lesson is that the opportunity extends beyond the analyzer itself. It includes the sample-processing technology, assay or cartridge, interpretation layer, and operating workflow required to make testing dependable in frontline settings.

The business opportunity is bigger than the device

A portable analyzer alone does not create a reliable diagnostic service.

For a solution to work in a village or PHC, the entire operating model must function: sample collection, consumables, trained operators, quality control, maintenance, result reporting, referral and follow-up.

This changes the investment lens.

A promising company must demonstrate not only that its technology works, but that it works consistently in real-world conditions, and that someone has a sustainable reason to pay for it.

The questions investors should ask are straightforward:

• Does the test produce clinically reliable results across relevant patient populations?

• Can frontline staff operate it with limited training?

• Is the cost per valid, actionable result competitive with existing alternatives?

• Are consumables available, affordable, and reliable?

• Will a hospital, laboratory network, government program, or another identifiable buyer pay for repeated use?

• Can the company support its devices after deployment and generate repeat demand?

A donated device or successful pilot can demonstrate potential. It does not, by itself, establish a scalable business.

Where patient capital can make a difference

Blood diagnostics is a deep-tech healthcare opportunity. Clinical validation, regulatory requirements, manufacturing quality, and field deployment can take time and capital before a company achieves meaningful commercial scale.

This creates a role for patient, milestone-linked capital.

Rather than funding scale prematurely, investors can support companies through clearly defined milestones: technical validation, prospective clinical studies, regulatory progress, manufacturing readiness, field performance, and repeat customer orders.

Three areas appear particularly worth exploring.

• Portable CBC and cell analysis

Technologies that deliver reliable blood counts using small samples and simplified workflows could expand diagnostic capabilities beyond conventional laboratories. The key is to demonstrate performance on real patient samples, including abnormal results, not just promising prototype demonstrations.

• Screening-to-confirmation pathways

Sickle-cell disease and thalassemia illustrate why screening is only one part of the solution. Confirmatory testing, counseling, referral and continuity of care matter just as much. Opportunities may emerge in connecting these steps into a dependable diagnostic pathway.

• The infrastructure around diagnostics

Consumables, quality-control systems, service networks, and connected workflows may matter as much to long-term adoption as the instrument itself. Companies that solve these operational challenges can help make decentralized testing sustainable beyond individual pilots.

These are investment hypotheses, not conclusions about which company will win. The strongest opportunities will emerge where a clearly defined clinical need meets validated technology, an identifiable buyer, and repeatable deployment economics.

From promising technology to dependable healthcare

India's primary-care network, public-health programs and growing diagnostic innovation ecosystem provide a foundation for distributed testing. Yet policy ambition does not automatically translate into adoption. Procurement, state-level implementation, operator capacity, maintenance and follow-up remain important constraints.

The next phase will require collaboration among innovators, healthcare providers, public systems, research institutions, philanthropic organizations and investors.

For investors, the task is to distinguish a compelling prototype from a dependable healthcare service. For founders, it means designing for the realities of frontline care rather than simply miniaturizing laboratory equipment.

And for the healthcare system, the goal is clear: ensure that a patient's access to an essential blood test depends less on how far they live from a laboratory.

The future of blood diagnostics will not be defined by the smallest analyzer alone. It will be defined by the ability to deliver reliable results at an affordable cost, where those results can make a difference.

Disclaimer

This article reflects my personal observations during a recent visit to Mundwa village in Nagaur, Rajasthan; my interactions with startups developing diagnostic technologies; and my experience supporting startups through targeted interventions in this domain.

The views expressed are personal and do not necessarily represent the views or positions of any organization with which I am associated.

While the thesis focuses on blood diagnostics, some of its broader observations may apply to other diagnostic technologies intended to serve last-mile communities in India.